KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Research & Development: 2010-2024

Historic Research & Development for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $70.7 million.

  • Emergent BioSolutions' Research & Development fell 2.17% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.2 million, marking a year-over-year decrease of 44.84%. This contributed to the annual value of $70.7 million for FY2024, which is 36.54% down from last year.
  • Emergent BioSolutions' Research & Development amounted to $70.7 million in FY2024, which was down 36.54% from $111.4 million recorded in FY2023.
  • Over the past 5 years, Emergent BioSolutions' Research & Development peaked at $237.9 million during FY2020, and registered a low of $70.7 million during FY2024.
  • Its 3-year average for Research & Development is $123.5 million, with a median of $111.4 million in 2023.
  • Per our database at Business Quant, Emergent BioSolutions' Research & Development increased by 5.17% in 2020 and then plummeted by 40.84% in 2023.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Research & Development stood at $237.9 million in 2020, then dropped by 1.13% to $235.2 million in 2021, then dropped by 19.94% to $188.3 million in 2022, then tumbled by 40.84% to $111.4 million in 2023, then plummeted by 36.54% to $70.7 million in 2024.